PeptideFactSheetsAn independent reference
Menu
Plain-English comparison

Peptides for cognition and brain research: evidence versus nootropic claims

A status-first comparison of Semax, Selank, oxytocin, and Humanin for cognition, social functioning, anxiety, and neuroprotection.

Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.

Overview

The phrase 'cognitive peptide' mixes several different goals: memory, attention, anxiety, social functioning, stroke recovery, and protection from neurodegeneration. Evidence for one outcome cannot answer the others.

Oxytocin has approved obstetric uses but no approved cognitive or autism indication. Semax and Selank have small, narrow human literatures and no FDA approval. Humanin treatment claims remain predominantly preclinical and observational.

Side-by-side comparison

Oxytocin
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Labor induction and postpartum uterine bleeding · Autism and social functioning · Social cognition and emotional processing

Semax
Not FDA approvedLimited or unclear evidence

Studied for

Ischemic stroke recovery · Neuroprotection in animal models · Cognition, attention, and memory claims

Selank
Not FDA approvedLimited or unclear evidence

Studied for

Anxiety disorders · Stress and emotional regulation · Cognitive and memory claims

Humanin
Preclinical researchMostly animal or lab research

Studied for

Neuroprotection in laboratory and animal models · Cognitive aging associations · Metabolic and insulin-signaling biology

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

Research areas

  • Social cognition and autism-related functioning
  • Anxiety and stress responses
  • Stroke recovery and neuroprotection
  • Cognitive aging and neurodegenerative mechanisms

Risks

  • A brain scan, gene-expression change, or animal memory task is not proof of better daily cognition in people.
  • The largest placebo-controlled intranasal oxytocin autism trial found no significant social or cognitive benefit.
  • FDA identifies safety and product-quality gaps for compounded Semax and Selank.

Open questions

  • Whether independently replicated responder groups exist for any cognitive or anxiety claim
  • Long-term neurologic and immune safety
  • Whether older or preclinical findings translate into meaningful modern clinical outcomes

Questions to ask a healthcare professional

1. What precise cognitive, behavioral, or functional outcome was measured?

2. Was the evidence from a large controlled human trial or a mechanistic model?

3. Was the exact molecule and formulation tested?

4. Did the study show a durable real-world benefit rather than a biomarker change?

Summary

None of these peptides is an FDA-approved cognitive enhancer. Dependable human outcomes and long-term safety evidence remain limited.

CompareMitochondrial peptides comparedHow FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.CompareGLP-1 peptides in Parkinson researchWhat the positive LIXIPARK trial and negative exenatide Phase 3 study say about GLP-1 neuroprotection claims.

Sources

  1. pubmedLarge intranasal oxytocin autism trial

    A 24-week placebo-controlled trial with no significant social or cognitive benefit.

  2. pubmedSmall Semax stroke study

    Older controlled human study with substantial design and reporting limitations.

  3. pubmedSmall randomized Selank anxiety study

    Narrow Russian-language clinical report without broad independent replication.

  4. fdaFDA: Semax and Selank compounding concerns

    Current FDA summary of route-specific safety and peptide-quality gaps.